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ABSTRACT 
Objective. We evaluated the ability of circulating stem cell levels to predict future micro and 
macrovascular complications in patients with type 2 diabetes. We further investigate the prognostic 
value of stem cells in a wide and heterogeneous cohort of patients, using a meta-analytic approach.  
Research design and methods. A cohort of 187 patients with type 2 diabetes was followed-up for 
a median of 3.3 years and 6.1 years for the evaluation of microvascular and macrovascular 
outcomes, respectively. The primary outcomes were onset or progression of any microangiopathy, 
and time to a first cardiovascular event. In addition, we meta-analysed all studies reporting the 
prognostic role of the CPC/EPC measure on cardiovascular outcomes and death in a heterogeneous 
population of 4451 patients at high cardiovascular risk. 
Results. New onset or progression of microangiopathy occurred in 70 patients (9.5% per year). 
After controlling the false discovery rate (FDR), baseline CD34+ CPCs and EPCs were significantly 
lower in patients with onset/progression of microalbuminuria and any microangiopathy. Patients 
with baseline CD34+ CPC or CD133+KDR+ EPC levels below median were more likely to 
experience worsening microangiopathy than those with high cell levels. In FDR-fully-adjusted 
analysis, CD34+ cells predicted onset/progression of microalbuminuria, retinopathy, and any 
microangiopathy. A first cardiovascular event occurred in 48 patients (4.5% per year). Patients with 
incident cardiovascular events had significantly lower CD34+ and CD34+CD133+ cells than those 
without. Patients with below median levels of CD34+ and CD34+CD133+ cells experienced higher 
rates of cardiovascular events. In Cox proportional hazard regression analyses, a reduced CD34+ 
and CD34+CD133+ cell count independently predicted future events. Addition of the CD34+ cell 
count to the UKPDS risk engine model improved C-statistics, continuous NRI and/or IDI. In the 
meta-analysis, reduced CPC/EPC levels were associated with a ~2 fold increased risk of future 
cardiovascular events and cardiovascular death and the most predictive phenotypes were CD34+ and 
CD34+CD133+. 
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Conclusions. In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem 
cells predicts worsening of microangiopathy and cardiovascular events up to 6 years later, and 
improves risk stratification. The meta-analysis suggests that prognostic impact of reduced stem cell 
levels was similar in diabetic and non-diabetic patients.  
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INTRODUCTION 
Diabetes is a major risk factor for the development of both cardiovascular and microvascular 
disease and confers a two to fourfold increase in the risk of coronary heart disease, stroke and 
peripheral artery disease. Even if cardiovascular events remain the leading cause of mortality, 
microvascular disease represents an independent predictor of vascular damage and contributes 
significantly to reduce the life expectation of diabetic patients. However, the risk of both macro and 
microvascular events varies considerable even within the diabetic population, providing a rationale 
for improving individual risk prediction using biomarkers.1,2  
The pathogenesis of vascular abnormalities in diabetic complications is generally focused on 
Brownlee's unifying hypothesis, whereby intracellular damage pathways are triggered by 
overproduction of oxygen reactive species from mitochondria. In contrast, vascular repair processes 
have been long neglected. However, vascular cell turnover plays a crucial role in maintaining the 
structural and functional integrity of endothelium and defects in such mechanism can be accelerated 
in patients with vascular noxae. Twenty years ago, Asahara et al. has isolated endothelial progenitor 
cells (EPCs) in peripheral blood for the first time.3 Since then, mounting studies have shown that 
circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs) are immature cells 
derived from bone marrow (BM), which have been involved both in angiogenesis and vascular 
repair processes.4 These cells are mobilized into the peripheral circulation in response to tissue 
damage and ischaemia.5 Once in the bloodstream, CPCs can differentiate into different phenotypes 
including endothelium, smooth muscle and cardiomyocytes, according to the additional antigenic 
phenotype they acquire (e.g. CD34+KDR+ for endothelial, CD34+ a-actin+ for smooth muscle and 
CD34+ c-met+ for potential cardiomyocyte progenitors).6-8 Yeh et al. demonstrated that human 
CD34+ injected into immunodeficient mice were able to differentiate into endothelium, smooth 
muscle and cardiomyocytes.9 In another study, human CD34+ were shown to contribute to 
neovascularization and were potent regulator of the host angiogenic and pro-inflammatory response 
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in a nude mouse model.10 Therefore, these evidences confirm that bone marrow CD34+ cells 
migrate into the circulation, undergo multi-lineage differentiation and are involved in vascular and 
tissue repair.  
In clinical studies, flow cytometry allows the identification and characterization of CPCs and EPCs 
through the analysis of differential expression of specific surface markers.7 Circulating progenitor 
cells (CPCs) are typically defined by the surface expression of the hematopoietic stem cell markers 
CD34 and/or CD133. Endothelial progenitor cells (EPCs) should be considered as a specific 
phenotype of CPCs with vascular endothelial commitment and are characterized by the co-
expression of CD34/CD133 and endothelial markers (most frequently the type 2 VEGF receptor 
KDR).  
In humans, the levels of CPCs and EPCs are reduced in patients with traditional cardiovascular risk 
factors,11-17 established cardiovascular disease18 or microangiopathy.19-22 Several studies have 
reported that CPCs and EPCs are reduced in number and are dysfunctional in patients with type 1 
and 2 diabetes. The reduction of CD34+ occurs early in the natural history of type 2 diabetes and 
can already be observed in subjects with impaired glucose tolerance.23 The depletion of progenitor 
cells persists over time and is significantly worse in patients with established vascular 
complications.18,24 Indeed, previous evidences by Fadini et al. showed that the levels of 
CD34+KDR+ negatively correlated to the severity of peripheral vascular damage in type 2 diabetic 
patients.25 Furthermore, the link between hyperglycaemia and EPCs dysfunction is supported by 
several studies on type 1 diabetes. The number of circulating CD34+KDR+ EPCs is reduced in 
young type 1 diabetic patients compared with controls, particularly in those with suboptimal 
glucose control,26 a longer diabetes duration, microangiopathy19,20 and initial surrogates signs of 
macroangiopathy.27,28 These studies suggest that levels of progenitor cells follow the natural history 
of atherosclerosis, from its subclinical stage to later complications of the plaque.29 However, if the 
relation between reduction of CPCs/EPCs and cardiovascular disease is well established, only few 
5 
 
studies investigated the effect on microangiopathy, suggesting conflicting results. In patients with 
chronic renal failure, Choi et al. demonstrated a significant impairment of EPCs, both in culture and 
circulation.30 Reinhard et al. found no alteration in early EPC cultures obtained from type 1 diabetic 
patients with nephropathy compared to those without.31 Dessapt et al. found lower levels of CD34+ 
and CD34+CD133+ in type 1 diabetic patients with microalbuminuria compared to those without,19 
and Makino et al. reported that CD34+ was an independent predictor of albuminuria progression in 
type 2 diabetic patients. As EPCs are characterized by pro-angiogenic activity, they may have 
opposite effects in the different stages of retinopathy. Several reports have shown increased levels 
of circulating (CD34+KDR+) and cultured EPCs in patients with proliferative retinopathy, 
suggesting a potential excess of EPCs may contribute to aberrant retinal angiogenesis, as 
demonstrated in animal models.32,33 However, studies are needed to support this hypothesis in 
humans. It must also be noted that no clinical study has so far evaluated the relationship between 
progenitor cells and diabetic neuropathy. This should be an area of great interest, in view of 
experimental studies showing that EPC-based approach may be a promising therapy for diabetic 
neuropathy.34,35 
The putative mechanisms for progenitor cell reduction include deranged differentiation, decreased 
survival, increased homing and impaired mobilization. An aberrant differentiation of blood-derived 
progenitor cells into endothelial cells has been observed in vitro models after exposure to 
hyperglycemia, and has been attributed to overactivity of the p38 MAP kinase.36,37 However, there 
is no evidence that this occurs in vivo.  In vitro studies showed that blood-derived progenitor cells 
undergo apoptosis when exposed to high glucose, and this is generally attributed to an increased 
oxidative stress, or downregulation of the PI3-K ⁄Akt signaling.38 However, this is true in vitro but 
no study has confirmed a reduced survival of diabetic progenitor cells in vivo, and a study by Fadini 
et al. showed that CD34+ cells from type 2 diabetic patients did not exhibit an increased rate of 
early apoptosis, evaluated by Annexin-V staining.24 The reduction of circulating progenitor cells 
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may also be the consequence of increased homing at the site of vascular injury. However, this 
mechanism cannot account for low progenitor cells in diabetes because it has been demonstrated 
that experimental type 1 and type 2 diabetes impaired homing and migration of EPCs to damaged 
tissue.39,40 Several studies have shown a defective mobilization of progenitor cells, suggesting that 
diabetes strongly affect bone marrow structure and function. Fadini et al. demonstrated that 
mobilization of EPCs after inducing ischemia was completely impaired in streptozotocin (type-1) 
diabetic rats when compared to healthy controls, and this defect was partially restored by insulin 
treatment. In the same study, the mobilization of EPCs was significantly blunted in diabetic rats 
after administration of granulocyte colony-stimulating factor (G-CSF).41 Diabetic patients are also 
unresponsive to the effects of G-CSF, which fails to mobilize CD34+ cells and EPCs.42,43 The 
impairment in progenitor cell mobilization may be a consequence of the deep remodeling induced 
by diabetes in bone marrow environment. In fact, both in mice44 and in humans,45 diabetic bone 
marrow is characterized by microangiopathy and alterations of the stem cell niche, that are similar 
to those observed in diabetic retinopathy.46 These evidences not only provide a mechanistic 
explanation for the impaired vascular repair by bone marrow-derived cells, but also identify bone 
marrow as a new potential site of diabetic microangiopathy. In this perspective, bone marrow 
dysfunction may represent the common soil for development of distant end-organ diabetic 
complications that together contribute to reduce the life expectancy of such patients.  
We herein evaluated the ability of CPCs/EPCs levels to predict future micro and macrovascular 
events in a cohort of 187 type 2 diabetic patients. Furthermore, we performed a meta-analysis of 
studies reporting the association between baseline progenitor cell levels and CVE or death in a 
heterogeneous population of 4551 patients.  
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MATERIALS AND METHODS 
Patient selection 
This pseudo-prospective study was approved by local institutions and ethical committee, and 
conducted in accordance to the principles of the Declaration of Helsinki. All patients provided 
informed consent. Patients included in the analysis were retrospectively selected from those 
regularly attending the Diabetes Outpatient Clinic of the University Hospital of Padova at 6-months 
intervals, over a period of ten years (2004-2014). Inclusion criteria were: T2D, age 30-80, both 
genders, at least 6 months observation, live status at follow-up, and availability of a baseline CPC / 
EPC determination. Exclusion criteria were: acute disease or infection at baseline; surgery, trauma 
or cardiovascular event in the 3 months prior to CPC/EPC determination; immune disorders or 
organ transplantation; cancer; baseline advanced liver (cirrhosis) or kidney (uremia) disease; 
pregnancy or lactation; inability to provide informed consent. We collected the following baseline 
data: age, sex, BMI, diabetes duration, HbA1c, urinary albumin/creatinine ratio (UACR), serum 
creatinine, concomitant risk factors, complications, and medications. The estimated glomerular 
filtration rate was calculated according to the CKD-EPI formula 47. Hypertension was defined as a 
systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg, or the use of anti-
hypertensive medications. Dyslipidemia was defined in the presence of a total cholesterol ≥200 
mg/dl, or LDL cholesterol ≥130 mg/dl, or triglycerides ≥150 mg/dl, or the use of statins/fibrates. 
Smoking was defined as habitual active smoking of 1 or more cigarettes per day. Retinopathy was 
defined on the basis of standardized digital retinal fundus images, examined and scored remotely by 
an experienced ophthalmologist, according to the ETDR classification 48. Somatic peripheral 
neuropathy was diagnosed, after exclusion of non-diabetic causes, in the presence of typical sensory 
or motor symptoms (numbness, tingling, or pain in the toes, feet, legs, hands, arms, and fingers, or 
wasting of the muscles of the feet or hands), confirmed by clinical examination (ankle reflexes, 
vibratory perception threshold, pinprick, and 10-g monofilament sensitivity) and eventual 
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determination of neural conduction velocity, in a minority of unclear cases 49. Autonomic 
neuropathy was screened annually using 4 routine cardiovascular autonomic function tests: deep 
breathing, lying-to-standing, Valsalva manoeuvre and orthostatic hypotension. Coronary artery 
disease (CAD) was defined as a history of myocardial infarction or angina, or evidence of 
significant coronary artery disease at coronary angiography. Peripheral arterial disease (PAD) was 
defined as a history of claudication or rest pain, or significant stenosis in leg arteries. Asymptomatic 
atherosclerosis was defined as the presence of carotid artery plaques (stenosis >15%) at routine 
ultrasound examination. Macroangiopathy was defined as the presence of CAD, PAD or 
asymptomatic atherosclerosis. 
 
Progenitor cell analysis 
 Circulating CPCs and EPCs were quantified by flow cytometry on whole blood samples.50 Briefly, 
after red blood cell lysis, cells were stained with anti-CD34 (Becton Dickinson), CD133 (Miltenyi 
Biotec), and KDR (R&D System) monoclonal antibodies. After gating CD34+ or CD133+ cells in 
the mononuclear cell population, cells were scored for dual or triple expression of KDR. For 
technical reasons, CD133 staining was not available in 18 patients. CPC were defined as CD34+, 
CD133+ and CD34+CD133+ cells, whereas EPC were defined as CD34+KDR+, CD133+KDR+ and 
CD34+CD133+KDR+ cells. Baseline progenitor cell levels were quantified by the same two trained 
operators using the same method and materials throughout the study, though lots of antibodies for 
KDR have changed. Reproducibility of this method has been reported previously, with CV ranging 
from 6.3% for CD34+ CPCs to 15-16% for EPCs 50. A representative example of the gating strategy 
is illustrated in Figure 1. We considered both relative (cells / 106 white blood cells, WBC), and 
absolute cell counts. Absolute levels were obtained by multiplying relative levels to WBC (/mL). 
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Definition of microvascular outcomes 
New onset or progression of microangiopathy was assessed at last available visit as compared to 
baseline, by retrieving electronic chart data reporting the results of routine screening performed 
every 6 months. Onset of nephropathy was defined as development of a pathologic UAER 
(UACR≥30 mg/g) in patients with a baseline UACR<30 mg/g. Progression of UAER was defined 
as worsening from micro- to macroalbuminuria. We also collected data on serum creatinine levels 
at last visit and determined the change in CKD-EPI eGFR from baseline. Onset/progression of CKD 
was defined as worsening category of eGFR from ≥60 to <60 ml/min/1.73 m2, or from 30-60 to <30 
ml/min/1.73 m2). Onset of retinopathy was defined as detection of retinopathy (any grade) in 
patients who were free from retinopathy at baseline. Progression of retinopathy was defined as any 
worsening in the ETDRS grade, or the need of photocoagulation therapy or intravitreal therapy, or 
onset of diabetic macular edema. Onset of neuropathy was defined as a new diagnosis of somatic or 
autonomic neuropathy in patients who were free from neuropathy at baseline. Progression of 
neuropathy was defined as the onset of autonomic neuropathy in patients with baseline somatic 
neuropathy, and vice-versa. Onset of microangiopathy was defined as a new diagnosis of 
nephropathy, retinopathy or neuropathy in patients free from all these complications at baseline, 
whereas progression of microangiopathy was defined as increasing number or severity of 
microangiopathic complications. To increase power in statistical analysis, onset and progression 
were always pooled together, under the term “progression”.  
 
Definition of macrovascular outcomes 
The primary outcome was time to a first cardiovascular event (all events). Secondary outcomes 
were the 3-point and 4-point MACE. The 3-point MACE (major cardiovascular events) was a 
composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. 
The 4-point MACE was a composite of the 3-point MACE or hospitalization for heart failure or 
unstable angina. All events included the 3-point MACE and hospitalization for any cardiovascular 
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cause. The cause of death was determined by the principal condition and was considered to be 
cardiovascular in case of: sudden death; death occurring up to 14 days after an acute myocardial 
infarction; death occurring in the context of clinically worsening symptoms and/or signs of heart 
failure; death occurring up to 30 days after a stroke; death due to another documented 
cardiovascular cause (e.g. dysrythmia, pulmonary embolism, or intervention). Any death not 
attributed to a non-cardiovascular cause were presumed to be cardiovascular. Nonfatal myocardial 
infarction was defined in the presence of at least 2 of the following 3 criteria: cardiac biomarker 
elevation; ECG changes consistent with new ischemia; imaging evidence of new non-viable 
myocardium or new wall motion abnormalities. Nonfatal stroke was defined as the rapid onset of a 
focal/global neurological deficit (change in level of consciousness, hemiplegia, hemiparesis, 
numbness or sensory loss affecting one side of the body; dysphasia/aphasia; hemianopia, other new 
neurological sign/symptom), with a duration of ≥24 hours (<24 hours if the event was associated 
with pharmacologic treatment, or in the presence of available brain imaging showing new 
hemorrhage or infarct, or resulting in death <fatal stroke>), and confirmed by a neurology specialist 
or by brain imaging. Unstable angina was defined as resting, new onset, or worsening angina, in the 
absence of elevation in cardiac biomarkers, and in the presence of new or worsening ST-T changes 
on ECG, or evidence of ischemia by cardiac imaging, or angiographic evidence of ≥70% stenosis in 
an epicardial coronary artery. Heart failure was defined in the presence of typical clinical 
manifestations or their worsening (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, 
pulmonary basilar crackles, jugular venous distension, third heart sound or gallop rhythm, 
radiologic evidence of worsening heart failure), needing new therapy or uptitration of doses 
(diuretics, inotropes, vasodilators), eventually supported by changes in biomarkers (e.g. brain 
natriuretic peptides). Other cardiovascular events considered included: unplanned coronary, 
peripheral or carotid revascularization and arrhythmia requiring hospitalization.  
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Statistical analysis 
Data are expressed as mean ± standard error, or as percentage where appropriate. Normality was 
checked with the Kolmogorov-Smirnov test. Non-normal variables were log transformed for 
statistical analysis. Comparisons between 2 groups were performed using the Student’s t test for 
continuous variables or chi-square for binary variables. As 6 progenitor cell phenotypes were 
always tested for each outcome, adjustment for type I error inflation due to multiple testing and 
false discovery rate (FDR) control were performed using the Benjamini-Hochberg (BH) procedure. 
ROC curves were used to assess the ability of stem/progenitor cell levels to discriminate patients 
with adverse outcomes. The best cut-offs were chosen as those that optimized the product of 
sensitivity and specificity. With n=187 patients, the probability was 80% that the study detected a 
difference at a 2 sided 5% significance level, if the true hazard ratio was 1.60, based on the 
assumption that the accrual period was 10 years the follow up period 6 years and the median event-
free survival time 4 years. Stem/progenitor cell levels were dichotomized as below/above the 
median value in order to divide the patients into equal groups. The Cox proportional hazard 
regression model was used to evaluate the predictive capacity of a low (below median) versus a 
high (above median) stem/progenitor cell level, independently from confounders. Potential 
confounders were variables associated with the outcome in the univariate logistic analysis at 
p<0.10. Discrimination improvement was assessed using C-statistics applied to time-to-event data, 
the integrated discrimination index (IDI) and the continuous net reclassification improvement (NRI) 
51. Statistical significance was accepted at p<0.05. SPSS version 22.0 and Microsoft Excel 2003 
were used.  
   
Meta-analysis 
We screened the literature for prospective observational studies reporting occurrence of 
cardiovascular events among patients whose levels of CPCs/EPCs were determined at baseline. 
Studies using enumeration of cultured endothelial colony-forming cells (CFU), often referred to as 
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“early EPCs”, “circulating angiogenic cells” or “pro-angiogenic cells”, were also considered. 
Eligible studies had to be reported in the English literature from 1997 to end of February 2016 and 
could include either patients undergoing coronary angiography for suspected coronary artery 
disease or acute coronary syndrome, or patients admitted for stroke, or patients without acute events 
but with cardiovascular risk factors. Eligible outcomes were: 1) CVE (defined as myocardial 
infarction, percutaneous or surgical coronary revascularisation, any acute coronary syndrome, heart 
failure, stroke, uncontrolled arrhythmia, cardiovascular death), 2) cardiovascular death, 3) death 
from any cause, 4) restenosis (defined as intra-stent luminal loss or stenosis progression accessed by 
angiography), 5) revascularization. We did not exclude a priori any study on the basis of 
methodological standards, sample size, duration of follow-up. We searched the MEDLINE database 
via PubMed up to 29 February 2016 using the following search terms: ("progenitor cells" or 
“CD34+ cells” or “stem cells”) and ("cardiovascular events" or "myocardial infarction" or "stroke" 
or "angina" or "tia" or "failure" or "hospitalization" or “restenosis” or “death” or “mortality”) and 
("follow-up" or "followed-up" or "incident" or "incidence"). This strategy was complemented by 
hand searching in the reference lists of retrieved articles and contact with authors. As 2 of the 
authors (AA and GPF) of the present article are also authors of potentially eligible studies, 
eligibility and risk of bias for such studies were assessed independently by an author with no 
secondary interest (MR), as recommended by the Cochrane Collaboration guidelines.52 We 
followed the MOOSE guidelines for performing and reporting results of observational studies.53 
Two reviewers (MR and GPF) independently extracted data from eligible articles (n=28) using a 
predefined coding protocol. Individual item disagreement between the two reviewers was resolved 
by consensus or consultation with a third author (AA). We extracted information on year of 
publication, number of patients at baseline, country, their mean age and percentage of males, the 
baseline prevalence of diabetes, hypertension, dyslipidemia, chronic kidney disease, smoke habit, 
coronary artery disease (proportion with previous coronary events), and the use of cardiovascular 
medications such as statins or blockers of the RAAS. We collected data on the phenotypic 
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characteristics and baseline levels of CPCs/EPCs, defined as low or high according to ROC curve 
cut-off, median value, or in relation to their subdivision into tertiles or quintiles. We extracted the 
reported relative risk, odds ratio or hazard ratio, and 95% confidence intervals (C.I.) from each 
study. For articles reporting multiple risk measures, we extracted risk measures for the pre-specified 
outcomes with the largest number of adjustment variables. When available, we checked the MACE 
breakdown to detect any significant imbalance in its composition. Studies wherein MACE 
contained a small percentage of hard events (myocardial infarction and stroke), were considered 
only for more specific outcomes (e.g. revascularization). We evaluated the quality of individual 
study reports according to REMARK guidelines for prognostic biomarker studies.54 We extracted 
details of 16 items related to the purpose of studies, population description, biomarker 
measurement, confounders, outcomes and analytic choice. We compared the effect of low versus 
high level of CPCs / EPCs on all pre-specified outcomes. The reported comparisons included risk 
estimates onto a standard scale (i.e. per 1 SD, per tertile, or per quintile), according to ROC curve 
cut-off, or per unit of change in cell count. To allow the comparison on a same scale, we 
standardized the risk expressed per unit of change using the attributable risk approach. The relative 
risk estimates of each study and their corresponding standard error (SE) were transformed to their 
natural logarithms to normalize distributions. Due to heterogeneity among studies, we used the 
random effect meta-analysis using the inverse variance method. In this approach, the weight given 
to each study is the inverse of the variance of the effect estimate. In general, the larger studies 
(smaller SE) are given more weight than smaller studies (larger SE), leading to a reduction of the 
imprecision of pooled effect estimate. However, for comparison, we also report summary statistics 
obtained using the fixed effect model, as suggested by Sterne et al.55 For each outcome, we 
performed an overall meta-analysis and up to five subgroups analysis: 1) considering only studies 
wherein patients without acute cardiovascular events were enrolled; 2) considering only studies 
reporting adjusted risk estimates onto a standard scale of effect; 3) considering only studies wherein 
patients with acute cardiovascular events were enrolled; 4) considering only higher-quality studies, 
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defined as having a REMARK score above the median value; 5) considering only studies wherein 
the MACE outcome was composed by >50% hard endpoints (myocardial infarction or stroke). All 
meta-analyses were performed using the software Revman version 5.3. Meta-regression analyses 
was performed under the random effect model to assess the relationship between the prognostic 
cardiovascular impact of CPCs / EPCs and covariates of interest. Outliers were screened and 
defined as previously described.56 
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RESULTS 
Baseline characteristics of enrolled patients 
Out of 257 total patients having a baseline progenitor cell determination initially retrieved, 187 met 
inclusion/exclusion criteria and had full data available. Reasons for exclusion were: age<30 (n=3) 
or >80 (n=15); T1D (n=12); dead status (n=18); follow-up duration <6 months (n=13) and missing 
data at follow-up (n=9). Baseline clinical characteristics of the study cohort are reported in Table 1. 
Mean age was 63 years and 67% of patients were males. The average diabetes duration was 10 
years and HbA1c indicated an overall fair glycemic control. At baseline, 58.8% of patients had 
macroangiopathy and 46.5% had at least one microangiopathic complication. 
 
Microvascular outcomes 
During a median follow-up of 3.3 years (interquartile range 1.8-5.6 years), a total of 70 patients 
(37.4%) experienced any progression of microangiopathy, equal to an annual rate of 9.5%. The 
annual rates of UAER, CKD, retinopathy and neuropathy progression were 2.9%, 3.0%, 3.8% and 
2.5%, respectively. Table 1 also shows clinical characteristics in patients divided according to 
progression or non-progression of microvascular complications. At baseline, progenitor cell 
phenotypes were generally not significantly associated with the prevalence of microangiopathy, 
with the exception of CD34+CD133+ CPCs, which were lower in patients with retinopathy or 
neuropathy than in those without. CD34+ CPCs were lower in patients with asymptomatic 
atherosclerosis than in those without (Figure 2). 
Progenitor cell levels according to microvascular outcomes. We first compared baseline progenitor 
cell counts in patients experiencing progression of each microangiopathy and in those without. 
Baseline CD34+ CPC levels were significantly lower in patients with progression of UAER and any 
microangiopathy, whereas FDR-unadjusted significant differences in relation to CKD, retinopathy, 
neuropathy disappeared after applying the BH procedure. EPC phenotypes were significantly lower 
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in patients with progression of UAER, any microangiopathy, whereas the association with 
neuropathy disappeared after FDR control (Figure 3).  
Rates of microvascular outcomes according to progenitor cell status. We then divided patients into 
equal groups based on median values of each CPC and EPC phenotype (baseline data in Table 2). In 
this univariate analysis, patients with low CD34+ CPCs had a higher chance of UAER, CKD, and 
any microangiopathy progression, than those with high CD34+ CPCs, whereas associations of low 
CD34+ CPCs with retinopathy and neuropathy progression rate disappeared after FDR control. 
Among EPC phenotypes, low CD133+KDR+ cells were associated with a significantly higher rate of 
UAER, CKD, and any microangiopathy progression, whereas a low CD34+CD133+KDR+ cell count 
remained only associated with progression of CKD after FDR control. 
In a logistic multivariable analysis, adjusted for age, sex, BMI, HbA1c, diabetes duration, 
prevalence of hypertension, dyslipidemia, smoking habit, baseline macroangiopathy, and follow-up 
duration, the CD34+ CPC count remained significantly associated with progression of UAER, 
retinopathy, neuropathy, and any microangiopathy. CD133+KDR+ EPCs levels remained 
significantly associated with progression of UAER, neuropathy, and any microangiopathy, whereas 
CD34+CD133+KDR+ cells remained significantly associated with progression of UAER, and any 
microangiopathy (Table 3).  
In patients with high CD34+ CPCs, the use of ACE inhibitors or ARB since baseline was associated 
with a significantly lower rate of microalbuminuria progression, whereas this protection was lost in 
patients with low CD34+ CPCs (Figure 4). The interaction between CD34+ cell count and 
ACEi/ARB therapy remained significant in the multivariable analysis (not shown). 
 
Macrovascular outcomes 
During a median follow-up period of 6.1 years (interquartile range 3.4-7.4 years), a total of 48 
cardiovascular events were registered, equal to an annual rate of 4.5%. The breakdown of all events 
was: 3 cardiovascular death, 5 non-fatal stroke, 10 non-fatal AMI, 16 hospitalization for hear 
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failure, 6 hospitalization of unstable angina, and 8 hospitalizations for other cardiovascular causes. 
The rate of 3-point and 4-point MACE are comparable to those reported in recent cardiovascular 
outcome trials wherein similar populations of patients were enrolled.57  
Progenitor cell levels according to cardiovascular outcomes. We first divided patients into those 
with or without adverse cardiovascular outcomes at follow-up (Table 1). Patients who experienced a 
cardiovascular event (primary endpoint) during observation had significantly lower relative and 
absolute levels of CD34+ cells, relative levels of CD133+ cells, and relative and absolute levels of 
CD34+CD133+ cells than did patients without an event at follow-up. After correction for multiple 
testing with the BH procedure, relative CD34+ and CD34+CD133+ cell counts remained 
significantly lower in patients with events. Owing to the smaller number of events, trend 
associations were detected with the 3-point and 4-point MACE, which were non-significant before 
or after BH correction (Figure 5A and 6A). No significant differences were noted for KDR-
expressing phenotypes. 
Rates of cardiovascular events according to progenitor cell status. We then divided patients into 
equal groups based on the median value for each progenitor cell phenotype and calculated the 
annual rate of incident cardiovascular outcomes (Figure 5B and 6B). The rate of all events (primary 
endpoint) was significantly higher in patients with low than in those with high relative levels of 
CD34+ and CD34+CD133+ cells, even after BH correction. The associations between low relative 
levels of CD34+ or CD133+ cells and a higher rate of the 3-point or 4-point MACE did not survive 
after BH correction (Figure 5B), nor did the associations between absolute levels of CD34+ cells 
and the rates of all events and 3-point MACE (Figure 6B). No significant differences were noted for 
KDR-expressing phenotypes. 
According to the area under curve (AUC) from ROC curves, the discrimination capacity of CD34+ 
cells against the primary outcome was higher than that of CD34+CD133+ cells (AUC [95% C.I.] 
0.687 [0.596-0.779] versus 0.617 [0.529-0.704]). The optimal cut-off value for CD34+ cell count 
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was 305 cells / 106 (sensitivity 75.4%; specificity 58.2%), or 2668 cells / ml (sensitivity 53.2%; 
specificity 72.9%). 
Analysis of event-free survival according to progenitor cell status. To evaluate whether low versus 
high progenitor cell levels predicted adverse cardiovascular outcomes independently of 
confounders, we used the Cox proportional hazard model. Variables associated with cardiovascular 
events at follow-up with p<0.10 were BMI, HbA1c, hypertension, albumin-creatinine ratio, eGFR, 
macroangiopathy, and several therapies (Table 1). Though determinants of the 3-point and 4-point 
MACE may be slightly different, these variables were chosen as covariates in the fully-adjusted 
model, because definition of the primary outcome included those of the secondary outcomes. Table 
4 shows hazard ratios (HR) with 95% C.I. for low versus high relative levels of progenitor cell 
phenotypes: low CD34+ cells and CD34+CD133+ cells independently predicted the primary 
outcome, with quite similar HRs. Figure 7 shows fully adjusted Kaplan-Meier curves. The HR 
remained statistically significant for CD34+CD133+ cells after BH correction. The associations with 
the 3-point and 4-point MACE were non-significant before or after BH correction. The associations 
of absolute CD34+ or CD34+CD133+ cells with cardiovascular outcomes were quantitatively 
similar, but statistically weaker (Table 4). KDR-expressing phenotypes were not predictive of 
adverse outcomes or sometimes showed a direct association with future cardiovascular events, not 
surviving correction for multiple testing.  
As clinical determinants of death may differ from those of cardiovascular events, we selected 
covariates with significance level <0.10 in the comparison of patients who were alive and those 
who were died at follow-up: age, dyslipidemia, neuropathy, peripheral arterial disease and therapy 
(secretagogues, beta-blockers, calcium antagonists). No significant association was detected 
between progenitor cell levels and death from any cause (Table 4). 
Discrimination improvement by addition of progenitor cell levels. We finally compared the 
discrimination capacity of the model described in Table 4 with and without inclusion of relative 
CD34+ cells, against the primary endpoint. C-statistics improved from 0.758 to 0.799 (p<0.001), the 
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continuous NRI improved by 35% (p=0.038) whereas IDI was not significantly improved (4.5%; 
p=0.059). Discrimination capacity was not significantly improved by addition of relative 
CD34+CD133+ cells (C-statistics from 0.767 to 0.781 [p=0.108]; NRI=28.9% [p=0.069]; IDI=4.2% 
[p=0.084]). Addition of relative CD34+ cell count to the CHD risk provided by the UKPDS risk 
engine significantly improved C-statistics (from 0.616 to 0.704; p<0.001), continuous NDI (46.8%, 
p=0.006), and IDI (7.2%; p<0.001). Addition of relative CD34+CD133+ cell count to the UKPDS 
risk significantly also improved C-statistics (from 0.590 to 0.642; p<0.001), continuous NDI 
(37.4%, p=0.019), and IDI (2.5%; p=0.022).  
 
Meta-analysis 
We identified 695 studies. One duplicate was excluded. Of the remaining studies, 666 were 
irrelevant to this review and were excluded on the basis of their titles and abstracts. Of the 
remaining, 7 studies were considered only for descriptive purpose due to missing data, and 21 were 
included in meta-analysis, for a total of 4,155 patients (Figure 8).  
Overall characteristics of included studies. The meta-analysis included 21 studies, for a total of 
4,155 patients (average pts/study = 198, median [IQR] = 154 [121-215]).58-77 Characteristics of 
studies included from meta-analysis are given in Table 5. The most important reason whereby 
studies initially retrieved were finally excluded from meta-analysis was the lack of a poolable risk 
estimate and impossibility to calculate such estimate from the data provided. Pooled cumulative 
clinical characteristics of the meta-analysed patient population are reported in Table 6. Four of the 
21 studies, (n=512 patients, 12.8% of the total population) were conducted in patients with acute 
coronary syndrome, acute myocardial infarction, or stroke.62,67,69,76 For the remainders, the 
underlying disease or condition was elective percutaneous intervention in 7/17 studies (n=795 
patients, 19.1%),59-61,64,71,73,75 elective coronary angiography for suspected CAD in 2/17 (n=1,412 
patients, 34.0%),70,74 end-stage renal disease in 4/17 studies (n=705 patients, 17.0%),65,66,68,77 
chronic heart failure in 1/17 studies (n=156 patients, 3.8%),58  and aortic stenosis in 1/17 study 
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(n=261 patients; 6.3%).78 One study included patients with and without chronic CVD at baseline,63 
and one study included both healthy subjects and patients with chronic or acute CVD.72 Five of 21 
studies considered multiple CPCs/EPCs phenotypes at the same time. Phenotypes most frequently 
used were CD34+ CPCs (6 studies) and CD34+KDR+ EPCs (12 studies). The outcome most 
commonly considered was the occurrence of future cardiovascular events (16 studies). 
Quality of included studies. According to a 16-item evaluation, modified from the REMARK 
guidelines to fit the purpose of this meta-analysis,54 the median (IQR) score was 10 (9-12). Studies 
had a good quality (>50% of studies) for the following items: pre-specified hypothesis, setting, 
inclusion/exclusion criteria, number of patients at each stage, details on manufacturers and assays 
for CPCs/EPCs, confounders, hierarchy of outcomes, univariate estimate and adjustment, rationale 
for group comparisons. Vice versa, quality was overall poor (<50% of studies) for: rationale for 
sample size, description of sample handling, endpoint validation and masking, handling of missing 
values (Figure 9). 
Cardiovascular events. Two studies reporting on CVE were excluded from this analysis because the 
MACE breakdown indicated an excessive contamination with non-hard events.58,69 The analysis 
was first conducted for each single cell phenotype and then summary statistics for all phenotypes 
were pooled together. The risk ratio of future cardiovascular events (random effect model) in 
patients with low versus high cell count was statistically significant for CD34+CD133+ CPCs (RR 
2.61 [1.44-4.74]), CD34+CD133+KDR+ EPCs (RR 7.91 [2.65-23.57]), and CFU (RR 1.18 [1.00-
1.39]), whereas it was not significant for CD34+, CD34+KDR+, and CD133+KDR+ cells. The latter 
showed significant heterogeneity among studies in the association with future cardiovascular 
events. When phenotype-specific risk estimates were pooled together, the overall risk ratio 
indicated that a low CPCs/EPCs count was associated with a significant 97% higher risk of future 
cardiovascular events (Figure 10).  
When the analysis was repeated excluding studies on patients with acute CVD, who have the 
highest risk for future events, the overall statistics was lower as expected but still significant (RR 
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1.71 [1.16-2.52]). When the analysis excluded studies wherein the risk estimate had to be 
calculated, the overall statistics was higher (RR 2.52 [1.56-4.06]) and highly significant. Limiting 
the analysis to studies with a REMARK score >10 yielded a risk ratio of 1.99 (1.25-3.16) (Figure 
11a). Such studies also had a more homogeneous definition of the composite cardiovascular 
outcome, with at least 50% composed by hard endpoints. 
According to the fixed effect model, the risk ratio would be significant for CD34+ (2.02 [1.43-2.85], 
p<0.001), CD34+CD133+ (2.61 [1.44-4.74], p=0.002), CD34+KDR+ (1.24 [1.07-1.43], p=0.003), 
CD34+CD133+KDR+ (7.91 [2.65-23.57], p<0.001). 
Cardiovascular and all-cause mortality. Four studies reported cardiovascular death in relation to 
baseline CPCs/EPCs. Altogether, they show an association between low versus high cell count and 
the risk for future cardiovascular death, yielding a pooled risk ratio of 1.87 (95% C.I. 1.15-3.02). 
The corresponding risk ratio according to the fixed-effect model was 1.45 (1.22-1.72). However, 
multiple studies were available only for CD34+KDR+ cells (n=3) and their association with 
cardiovascular death was highly heterogeneous, yielding a non-significant pooled risk ratio (Figure 
12a).  
Data on all-cause mortality was available for most phenotypes. The pooled risk ratio of future death 
in patients with low versus high cell count was statistically significant for CD34+ (RR 3.40 [1.99-
5.83]), CD34+CD133+ CPCs (2.56 [1.26-5.17]), and CD34+CD133+KDR+ EPCs (RR 1.36 [1.21-
1.53]). Some EPC phenotypes showed paradoxical opposite trend associations with future death 
from any cause, and a large heterogeneity among studies was found. As a result, the overall 
summary statistics for all phenotypes was marginally significant with the random-effect model 
(Figure 12b). According to the fixed-effect model, the pooled risk ratio for all phenotypes would be 
1.37 (1.23-1.52; p<0.001). When the random-effect model analysis excluded studies wherein the 
risk estimate had to be calculated, the overall statistics was 1.75 (1.23-2.49; p=0.002) (Figure 11b).  
Restenosis and revascularization. A few studies reported the risk of restenosis after percutaneous 
intervention and/or the need for future revascularization in patients with baseline acute or chronic 
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CVD. The association between low versus high CPCs/EPCs levels and restenosis was highly 
variable according the cellular phenotype, ranging from a significant protection for low CD34+ cells 
to a significant harm for low CD34+CD133+KDR+ cells or CFU. The overall statistics showed a 
trend increased risk of future restenosis in patients with low versus high CPCs/EPCs, with high and 
significant heterogeneity (Figure 13a). Similar results were obtained when the analysis excluded 
studies wherein the risk estimate had to be calculated, whereas limiting the analysis to higher 
quality studies yielded a risk ratio of RR 4.33 (4.01-4.69) for restenosis associated with low versus 
high cell count (Figure 11c). According to the fixed-effect model, the risk of restenosis associated 
with a low CPCs/EPCs cell count would be 2.97 (2.77-3.17). 
Data on the risk for future revascularization was available only for 3 phenotypes: there was a non-
significant trend association of reduced risk in patients with low CPCs/EPCs, but heterogeneity was 
high and statistically significant (Figure 13b). Excluding studies conducted in acute CVD patients 
or studies for which the risk estimate had to be calculated did not change the results using the 
random effect model (Figure 11d), though it yielded a significant risk ratio using the fixed effect 
model (RR 1.21 [1.02-1.43]). 
Meta-regression analysis. A meta-regression was conducted to detect whether any overall 
characteristic of study populations consistently modulated the risk estimate. As robustness of meta-
regression relies on the number of studies included, we only analyzed the risk ratio for the most 
commonly used progenitor cell phenotype (CD34+KDR+ EPCs) and the most common outcome 
(CVE). With the random effect model, the log of risk ratio was significantly associated with the 
percentage of male patients (direct correlation, p=0.002), the percentage of patients with a previous 
AMI (direct correlation, p=0.002), and with the percentage of patients on statin (inverse association, 
p<0.0001) (Figure 14). No statistically significant outlier was detected in this meta-regression. 
Excluded studies. Excluded studies reported data on the relation between CPCs/EPCs levels and 
functional outcome after acute myocardial infarction or stroke. Four studies were conducted on a 
total of n=309 patients with AMI, overall showing that high CD34+/CD133+ CPCs predicted 
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improvements in regional or global left ventricular function,79-81 and in coronary flow reserve.82 
One study found that mobilization of EPCs during acute ischemia was significantly lower in 
patients who developed restenosis,83 whereas a small study in patients with stable angina showed 
that EPC levels directly correlated with the degree of restenosis.84 In one study conducted in 
patients with acute ischemic stroke, a low number of baseline EPCs predicted worse functional 
outcomes after 6 months.85 
Biases. The number of studies available for which a given CPC / EPC phenotype was assessed in 
relation to a given outcome was limited. In funnel plots showing all phenotypes simultaneously 
(Figure 15), there is a suggestion of missing studies on the bottom left hand side of the plot. Since 
most of this area contains regions of high significance, publication bias is unlikely to be the 
underlying cause of asymmetry. Heterogeneity likely arose from selective outcome and analysis 
reporting, and poor quality of some studies.55 
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DISCUSSION 
We demonstrated that reduced levels of circulating progenitor cell phenotypes, including EPCs, 
predict future worsening of microangiopathy and cardiovascular events in patients with T2D. The 
CD34+ cell count outperformed other CPC and EPC phenotypes in prediction of microvascular 
outcomes, likely because of its higher reproducibility and stability 4,50. Indeed, after applying the 
most stringent FDR control, adjusting simultaneously for the 6 progenitor phenotypes and 5 
outcomes tested (equal to 30 multiple comparisons), CD34+ cells remained significantly associated 
with UAER, retinopathy, and microangiopathy progression in all univariate and multivariate 
analyses. Interestingly, we also found that reduction in CD34+ CPCs abolished the protective effects 
of ACE inhibitors/ARBs on UAER progression, though this interaction needs to be explored 
further.  
Previous works have shown associations between circulating progenitor cell levels and 
cardiovascular outcomes 70,74,86. Our study validates the clinical meaning of circulating stem cells 
defects in diabetic patients on long-term follow-up (up to 12 years). This is important because the 
majority of events occurred after 5 years of observation and we show that stem cell performance as 
biomarkers was not diluted over time. By analysing multiple phenotypes, we confirm that the 
CD34+ and CD34+CD133+ phenotypes are those provided with the strongest prognostic power, 
whereas KDR-expressing phenotypes, sometimes referred to as EPCs 4, did not predict 
cardiovascular outcomes, despite they are believed to be vasculoregenerative 87,88. This discrepancy 
is counterintuitive but has different plausible explanations.7 First, CPCs could reflect the healthy of 
bone marrow better than EPCs.89 Second, the number of circulating KDR+EPCs is lower than CPCs 
and their enumeration has higher variability, in particular for CD34+CD133+KDR+. Furthermore, 
KDR+ staining is not clinical-grade and inter-lots variations may occur for anti-KDR antibodies. 
Conversely, enumeration of CD34+ cells is more standardised, according to International Society 
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for Hematotherapy and Graft Engineering (ISHAGE) protocol, and is routinely available in most 
hospital laboratories.90 
The addition of CD34+ cell level to traditional UKPDS model of risk assessment significantly 
improves the event prediction (as determined by C-statistics, NRI and IDI) and therefore is 
expected to perform well as a clinical biomarker.   
We detected weaker associations between low stem cell levels and the 3-point or 4-point MACE 
and non-significant trend associations with death, because of the small number of events. It is also 
important to note that, owing to the large number of cell phenotypes tested, we had to correct for the 
false discovery rate. Focusing on associations that survived after BH correction allows for more 
robust conclusions from a statistical perspective.  
The meta-analysis of longitudinal studies, including 4,155 patients followed for an average of 2 
years, showed that a reduction in the levels of circulating CD34+ and CD34+CD133+ cells was 
associated with a ~2 fold increased risk of future cardiovascular events and death 91. In meta-
regression analyses, we detected no correlation between the prevalence of diabetes and HRs, 
suggesting that the prognostic impact of reduced stem cell levels was similar in diabetic and non-
diabetic patients 91. The association between low CPCs/EPCs and reduced risk for future 
revascularization observed in meta-analysis is counter-intuitive. However, differences in the clinical 
setting (acute versus chronic CVD) and in progenitor cell phenotype may account for this 
discrepancy. Biologically, reduction of vasculoprotective cells may prevent successful 
revascularization, by inducing a more severe and occlusive atherosclerosis, less amenable to 
surgical or endovascular intervention. 
Observational studies indicate that microangiopathy contributes to the risk of MACE in diabetes 92. 
While this is most obvious for CKD 93, the reasons whereby the presence of retinopathy increases 
the risk of myocardial infarction 94 are less clear. In addition, about 40% of excess mortality in 
diabetes is attributable to non-vascular causes 95, onto which microangiopathy may play a role. A 
common pathogenic ground for micro- and macroangiopathy has been postulated, and we 
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hypothesize that CPCs are candidate mediators of multi-organ complications in diabetes 96,97. 
Recently, the BM has emerged as a site of diabetic end-organ damage, and BM dysfunction 
accounts for the CPC reduction seen in diabetic patients 98. Interestingly, BM remodelling includes 
neurovascular changes and strongly resembles microangiopathy seen in the kidney and retina 44,45,99. 
The present study provides new evidence in support of a model wherein the BM acts as a central 
housekeeper of organismal health, whereas BM failure can link disparate end-organ complications.  
However, although progenitor cells have been shown to predict adverse long-term diabetic 
outcomes, whether CPC stimulation is able to modify the natural history of chronic complications 
in diabetic patients is still unknown. This is a relevant challenge that we need to further investigate 
considering the ancillary effects of known therapies on CPC levels. For example, dipeptidyl 
peptidase 4 (DPP-4) inhibitors and peroxisome proliferation activator receptor γ (PPAR-γ) agonists 
have shown the capacity to increase EPCs levels, acting on several pathways that are impaired in 
diabetic patients.100,101 Similarly, intensive statin therapies seem to increase the levels of EPCs 
independently by lipid-lowering action of such drugs.102 In a clinical prospective, these evidences 
highlight the need for an individualization of therapy based on individual cardiovascular risk 
profile.   
Limitations of this study need to be acknowledged. Data collection was formally retrospective, but 
routine follow-up of patients after the baseline CPCs/EPCs analysis allowed a pseudo-prospective 
design. The absolute need to analyze progenitor cells in fresh blood samples discourages truly 
prospective studies with adequate follow-up to detect disease progression, whereas our pseudo-
prospective study is the longest ever performed using CPCs/EPCs as biomarkers. However, accrual 
time was very long and follow-up duration variable among patients, thus precluding time-dependent 
analyses and possibly increasing the risk of bias. Our findings may not be generalizable also 
because BM impairment and progenitor cell pauperization is a typical feature of aging and age-
associated diseases 103. As aging contributes to microangiopathy in T2D, it is unclear whether 
similar findings would apply to a younger population of T1D patients. In addition, the relatively 
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small sample size prevented separated analyses for onset and progression of microangiopathy, 
disease severity, and hard endpoints (such as visual loss, dialysis, or amputations). Finally, changes 
in antibody lots and updates in FACS system setup over time may have generated some 
heterogeneity in progenitor cell quantification, especially for KDR staining, whereas CD133 
staining was missing in about 10% of cases.  
In conclusion, we show that low CPC and EPC levels predict microvascular and macrovascular 
outcomes in T2D. These data support the importance of the endogenous vascular regenerative 
capacity, mediated by BM-derived cells, in the global burden of diabetic complications 96. Our 
meta-analysis suggests that prognostic impact of reduced stem cell levels is similar in diabetic and 
non-diabetic patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
REFERENCES 
1. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects 
with type 2 diabetes. J Am Heart Assoc 2012; 1(1): 8-15. 
2. Boyko EJ, Meigs JB. Does diabetes always confer coronary heart disease risk equivalent to 
a prior myocardial infarction?: implications for prevention. Diabetes Care 2011; 34(3): 782-4. 
3. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells 
for angiogenesis. Science 1997; 275(5302): 964-7. 
4. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell 
phenotypes for therapeutic and diagnostic use. Circ Res 2012; 110(4): 624-37. 
5. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of 
bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5(4): 434-
8. 
6. Cesselli D, Beltrami AP, Rigo S, et al. Multipotent progenitor cells are present in human 
peripheral blood. Circ Res 2009; 104(10): 1225-34. 
7. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical notes on 
endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008; 
197(2): 496-503. 
8. Wojakowski W, Tendera M, Michalowska A, et al. Mobilization of CD34/CXCR4+, 
CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and 
endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 
2004; 110(20): 3213-20. 
9. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of 
human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and 
smooth muscle cells in vivo. Circulation 2003; 108(17): 2070-3. 
29 
 
10. Popa ER, Harmsen MC, Tio RA, et al. Circulating CD34+ progenitor cells modulate host 
angiogenesis and inflammation in vivo. J Mol Cell Cardiol 2006; 41(1): 86-96. 
11. Di Stefano R, Barsotti MC, Felice F, et al. Smoking and endothelial progenitor cells: a 
revision of literature. Curr Pharm Des 2010; 16(23): 2559-66. 
12. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor 
cells from healthy smokers exhibit impaired functional activities. Atherosclerosis 2006; 187(2): 
423-32. 
13. Pirro M, Schillaci G, Menecali C, et al. Reduced number of circulating endothelial 
progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens 2007; 
25(10): 2093-9. 
14. Lee CW, Huang PH, Huang SS, et al. Decreased circulating endothelial progenitor cell 
levels and function in essential hypertensive patients with electrocardiographic left ventricular 
hypertrophy. Hypertens Res 2011; 34(9): 999-1003. 
15. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of 
endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci 
(Lond) 2004; 107(3): 273-80. 
16. Muller-Ehmsen J, Braun D, Schneider T, et al. Decreased number of circulating progenitor 
cells in obesity: beneficial effects of weight reduction. Eur Heart J 2008; 29(12): 1560-8. 
17. Egan CG, Lavery R, Caporali F, et al. Generalised reduction of putative endothelial 
progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008; 
51(7): 1296-305. 
18. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in 
peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45(9): 1449-
57. 
19. Dessapt C, Karalliedde J, Hernandez-Fuentes M, et al. Circulating vascular progenitor cells 
in patients with type 1 diabetes and microalbuminuria. Diabetes Care 2010; 33(4): 875-7. 
30 
 
20. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial 
progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci 2009; 
50(1): 392-8. 
21. Makino H, Okada S, Nagumo A, et al. Decreased circulating CD34+ cells are associated 
with progression of diabetic nephropathy. Diabet Med 2009; 26(2): 171-3. 
22. Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating Progenitor Cell Count 
Predicts Microvascular Outcomes in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2015; 
100(7): 2666-72. 
23. Fadini GP, Pucci L, Vanacore R, et al. Glucose tolerance is negatively associated with 
circulating progenitor cell levels. Diabetologia 2007; 50(10): 2156-63. 
24. Fadini GP, Boscaro E, de Kreutzenberg S, et al. Time course and mechanisms of circulating 
progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010; 33(5): 1097-
102. 
25. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells 
as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006; 26(9): 2140-
6. 
26. Hortenhuber T, Rami-Mehar B, Satler M, et al. Endothelial progenitor cells are related to 
glycemic control in children with type 1 diabetes over time. Diabetes Care 2013; 36(6): 1647-53. 
27. Palombo C, Kozakova M, Morizzo C, et al. Circulating endothelial progenitor cells and 
large artery structure and function in young subjects with uncomplicated type 1 diabetes. 
Cardiovasc Diabetol 2011; 10: 88. 
28. Sibal L, Aldibbiat A, Agarwal SC, et al. Circulating endothelial progenitor cells, endothelial 
function, carotid intima-media thickness and circulating markers of endothelial dysfunction in 
people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 
2009; 52(8): 1464-73. 
31 
 
29. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural 
history of atherosclerosis. Atherosclerosis 2007; 194(1): 46-54. 
30. Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of 
endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 
2004; 24(7): 1246-52. 
31. Reinhard H, Jacobsen PK, Lajer M, et al. Endothelial progenitor cells in long-standing 
asymptomatic type 1 diabetic patients with or without diabetic nephropathy. Nephron Clin Pract 
2011; 118(3): c309-14. 
32. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote 
proliferative retinopathy. J Clin Invest 2005; 115(1): 86-93. 
33. Liu X, Li Y, Liu Y, et al. Endothelial progenitor cells (EPCs) mobilized and activated by 
neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am J 
Pathol 2010; 176(1): 504-15. 
34. Jeong JO, Kim MO, Kim H, et al. Dual angiogenic and neurotrophic effects of bone 
marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 2009; 119(5): 699-
708. 
35. Naruse K, Hamada Y, Nakashima E, et al. Therapeutic neovascularization using cord blood-
derived endothelial progenitor cells for diabetic neuropathy. Diabetes 2005; 54(6): 1823-8. 
36. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived 
endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol 
Med 2009; 15(5-6): 152-9. 
37. Seeger FH, Haendeler J, Walter DH, et al. p38 mitogen-activated protein kinase 
downregulates endothelial progenitor cells. Circulation 2005; 111(9): 1184-91. 
38. Krankel N, Adams V, Linke A, et al. Hyperglycemia reduces survival and impairs function 
of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 2005; 25(4): 698-703. 
32 
 
39. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by 
healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007; 56(4): 960-7. 
40. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial 
progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 
2007; 117(5): 1249-59. 
41. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after 
hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006; 49(12): 3075-84. 
42. Fadini GP, Albiero M, Vigili de Kreutzenberg S, et al. Diabetes impairs stem cell and 
proangiogenic cell mobilization in humans. Diabetes Care 2013; 36(4): 943-9. 
43. Fadini GP, Avogaro A. Diabetes impairs mobilization of stem cells for the treatment of 
cardiovascular disease: a meta-regression analysis. Int J Cardiol 2013; 168(2): 892-7. 
44. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow 
microangiopathy. Arterioscler Thromb Vasc Biol 2010; 30(3): 498-508. 
45. Spinetti G, Cordella D, Fortunato O, et al. Global remodeling of the vascular stem cell niche 
in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. 
Circ Res 2013; 112(3): 510-22. 
46. Mangialardi G, Katare R, Oikawa A, et al. Diabetes causes bone marrow endothelial barrier 
dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler 
Thromb Vasc Biol 2013; 33(3): 555-64. 
47. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med 2009; 150(9): 604-12. 
48. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of 
the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic 
Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 786-806. 
49. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American 
Diabetes Association. Diabetes Care 2005; 28(4): 956-62. 
33 
 
50. Fadini GP, de Kreutzenberg SV, Coracina A, et al. Circulating CD34+ cells, metabolic 
syndrome, and cardiovascular risk. Eur Heart J 2006; 27(18): 2247-55. 
51. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added 
predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. 
Stat Med 2008; 27(2): 157-72; discussion 207-12. 
52. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2011; 
Version 5.1.0. 
53. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE) group. JAMA 2000; 283(15): 2008-12. 
54. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for 
Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9(5): 
e1001216. 
55. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting 
funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002. 
56. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth 
Methods 2010; 1(2): 112-25. 
57. Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate 
diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol 2016; 15(1): 111. 
58. Alba AC, Lalonde SD, Rao V, Walter SD, Guyatt GH, Ross HJ. Changes in circulating 
progenitor cells are associated with outcome in heart failure patients: a longitudinal study. Can J 
Cardiol 2013; 29(12): 1657-64. 
59. Bonello L, Harhouri K, Baumstarck K, et al. Mobilization of CD34+ KDR+ endothelial 
progenitor cells predicts target lesion revascularization. J Thromb Haemost 2012; 10(9): 1906-13. 
60. Briguori C, Testa U, Riccioni R, et al. Correlations between progression of coronary artery 
disease and circulating endothelial progenitor cells. FASEB J 2010; 24(6): 1981-8. 
34 
 
61. Chiang CH, Huang PH, Chiu CC, et al. Reduction of circulating endothelial progenitor cell 
level is associated with contrast-induced nephropathy in patients undergoing percutaneous coronary 
and peripheral interventions. PLoS One 2014; 9(3): e89942. 
62. Cuadrado-Godia E, Regueiro A, Nunez J, et al. Endothelial Progenitor Cells Predict 
Cardiovascular Events after Atherothrombotic Stroke and Acute Myocardial Infarction. A 
PROCELL Substudy. PLoS One 2015; 10(9): e0132415. 
63. Fadini GP, de Kreutzenberg S, Agostini C, et al. Low CD34+ cell count and metabolic 
syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009; 207(1): 213-
9. 
64. Haine SE, Van Craenenbroeck EM, Hoymans VY, et al. Levels of circulating CD34+/KDR+ 
cells do not predict coronary in-stent restenosis. Can J Cardiol 2014; 30(1): 102-8. 
65. Lee HJ, Kim W, Kim WS, et al. Circulating Endothelial Progenitor Cell Levels Predict 
Cardiovascular Events in End-Stage Renal Disease Patients on Maintenance Hemodialysis. 
Nephron 2015; 130(3): 151-8. 
66. Lorenzen J, David S, Bahlmann FH, et al. Endothelial progenitor cells and cardiovascular 
events in patients with chronic kidney disease--a prospective follow-up study. PLoS One 2010; 
5(7): e11477. 
67. Marti-Fabregas J, Delgado-Mederos R, Crespo J, et al. Circulating endothelial progenitor 
cells and the risk of vascular events after ischemic stroke. PLoS One 2015; 10(4): e0124895. 
68. Maruyama S, Taguchi A, Iwashima S, et al. Low circulating CD34+ cell count is associated 
with poor prognosis in chronic hemodialysis patients. Kidney Int 2008; 74(12): 1603-9. 
69. Padfield GJ, Tura-Ceide O, Freyer E, et al. Endothelial progenitor cells, atheroma burden 
and clinical outcome in patients with coronary artery disease. Heart 2013; 99(11): 791-8. 
70. Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and risk of 
mortality in a population with coronary artery disease. Circ Res 2015; 116(2): 289-97. 
35 
 
71. Pelliccia F, Pasceri V, Rosano G, et al. Endothelial progenitor cells predict long-term 
prognosis in patients with stable angina treated with percutaneous coronary intervention: five-year 
follow-up of the PROCREATION study. Circ J 2013; 77(7): 1728-35. 
72. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating 
endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical 
importance of endogenous vascular repair. Circulation 2005; 111(22): 2981-7. 
73. Schober A, Hoffmann R, Opree N, et al. Peripheral CD34+ cells and the risk of in-stent 
restenosis in patients with coronary heart disease. Am J Cardiol 2005; 96(8): 1116-22. 
74. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and 
cardiovascular outcomes. N Engl J Med 2005; 353(10): 999-1007. 
75. Wu CC, Huang PH, Lai CL, Leu HB, Chen JW, Lin SJ. The impact of endothelial 
progenitor cells on restenosis after percutaneous angioplasty of hemodialysis vascular access. PLoS 
One 2014; 9(6): e101058. 
76. Yu CW, Choi SC, Hong SJ, et al. Cardiovascular event rates in patients with ST-elevation 
myocardial infarction were lower with early increases in mobilization of Oct4(high)Nanog(high) 
stem cells into the peripheral circulation during a 4-year follow-up. Int J Cardiol 2013; 168(3): 
2533-9. 
77. Lu CL, Leu JG, Liu WC, et al. Endothelial Progenitor Cells Predict Long-Term Mortality in 
Hemodialysis Patients. Int J Med Sci 2016; 13(3): 240-7. 
78. Shimoni S, Bar I, Meledin V, Derazne E, Gandelman G, George J. Circulating Endothelial 
Progenitor Cells and Clinical Outcome in Patients with Aortic Stenosis. PLoS One 2016; 11(2): 
e0148766. 
79. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells 
after myocardial infarction and left ventricular function. Eur Heart J 2005; 26(12): 1196-204. 
36 
 
80. Wyderka R, Wojakowski W, Jadczyk T, et al. Mobilization of CD34+CXCR4+ 
stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year 
follow-up of patients with acute myocardial infarction. Mediators Inflamm 2012; 2012: 564027. 
81. Grabczewska Z, Debski R, Goralczyk K, Swiatkiewicz I, Kubica J. Does mobilisation of 
CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the 
direction of left ventricular ejection fraction and wall motion score index changes in patients with 
myocardial infarction? Kardiol Pol 2013; 71(5): 464-71. 
82. Jeong HS, Hong SJ, Park JH, et al. Correlation between circulating angiogenic cell 
mobilizations and recovery of coronary flow reserve in patients with acute myocardial infarction. 
Circ J 2012; 76(5): 1213-21. 
83. Wojakowski W, Pyrlik A, Krol M, et al. Circulating endothelial progenitor cells are 
inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute 
coronary syndromes treated with EPC-capture stents (JACK-EPC trial). Minerva Cardioangiol 
2013; 61(3): 301-11. 
84. De Maria GL, Porto I, Burzotta F, et al. Dual role of circulating endothelial progenitor cells 
in stent struts endothelialisation and neointimal regrowth: a substudy of the IN-PACT CORO trial. 
Cardiovasc Revasc Med 2015; 16(1): 20-6. 
85. Tsai NW, Hung SH, Huang CR, et al. The association between circulating endothelial 
progenitor cells and outcome in different subtypes of acute ischemic stroke. Clin Chim Acta 2014; 
427: 6-10. 
86. Hayek SS, MacNamara J, Tahhan AS, et al. Circulating Progenitor Cells Identify Peripheral 
Arterial Disease in Patients With Coronary Artery Disease. Circ Res 2016; 119(4): 564-71. 
87. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ 
endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006; 
98(3): e20-5. 
37 
 
88. Madeddu P, Emanueli C, Pelosi E, et al. Transplantation of low dose CD34+KDR+ cells 
promotes vascular and muscular regeneration in ischemic limbs. FASEB J 2004; 18(14): 1737-9. 
89. Fadini GP. A look at the bone marrow predicts the global outcome. Circ Res 2015; 116(2): 
232-4. 
90. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for 
CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft 
Engineering. J Hematother 1996; 5(3): 213-26. 
91. Rigato M, Avogaro A, Fadini GP. Levels of Circulating Progenitor Cells, Cardiovascular 
Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. Circ Res 2016; 
118(12): 1930-9. 
92. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular 
events in type 2 diabetes? Atherosclerosis 2011; 218(1): 13-8. 
93. Solini A, Penno G, Bonora E, et al. Diverging association of reduced glomerular filtration 
rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the 
renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 
2012; 35(1): 143-9. 
94. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and 
the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 
2007; 30(7): 1742-6. 
95. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of 
cause-specific death. N Engl J Med 2011; 364(9): 829-41. 
96. Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of 
diabetes. Lancet Diabetes Endocrinol 2013; 1(1): 71-8. 
97. Fadini GP, Avogaro A. It is all in the blood: the multifaceted contribution of circulating 
progenitor cells in diabetic complications. Exp Diabetes Res 2012; 2012: 742976. 
38 
 
98. Fadini GP, Ferraro F, Quaini F, Asahara T, Madeddu P. Concise review: diabetes, the bone 
marrow niche, and impaired vascular regeneration. Stem Cells Transl Med 2014; 3(8): 949-57. 
99. Albiero M, Poncina N, Tjwa M, et al. Diabetes causes bone marrow autonomic neuropathy 
and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014; 63(4): 1353-
65. 
100. Esposito K, Maiorino MI, Di Palo C, et al. Effects of pioglitazone versus metformin on 
circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 
diabetes--a randomized controlled trial. Diabetes Obes Metab 2011; 13(5): 439-45. 
101. Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by 
mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 2013; 229(1): 23-9. 
102. Briguori C, Quintavalle C, D'Alessio F, et al. Impact of statin therapy intensity on 
endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The 
REMEDY-EPC late study. Int J Cardiol 2017; 244: 112-8. 
103. Ballard VL, Edelberg JM. Stem cells and the regeneration of the aging cardiovascular 
system. Circ Res 2007; 100(8): 1116-27. 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
FIGURES 
Figure 1. Representative FACS plots. Representative analyses of circulating stem/progenitor cell 
identification and enumeration from a patient without (A) and with (B) cardiovascular events at 
follow-up. After gating lymphocytes and monocytes in the FSC versus SSC morphologic plot 
(where 5 x 105 events are shown), total CD34+ cells were identified and scored (a parallel analysis 
was performed for total CD133+ cells). Gated CD34+ cells were then examined for expression of 
CD133 and KDR. Here, CD34+CD133+ cell count derive from the sum of CD34+CD133+KDR+ 
and CD34+CD133+KDR- events. 
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Figure 2. Association between progenitor cells levels and complications at baseline. Only 
significant associations are shown. *p<0.05. 
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Figure 3. Associations between progenitor cell levels and progression of microangiopathy. The upper lane reports mean±SEM CPC and EPC 
levels in patients without (white) and with (black) progression of each microvascular complication during follow-up. The lower lane reports annual 
incidence of each microvascular disease progression in patients categorized as having high or low CPC/EPC cells, based on median levels. *p<0.05 
in the indicated paired comparisons; # not significant after false discovery rate correction with the BH procedure. 
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Figure 4. Univariate interaction between high (above median) versus low (below median) CD34+ 
CPC count and use of ACE inhibitors / ARBs in determining the rate of onset/progression of 
microalbuminuria. *p<0.05 as indicated. 
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Figure 5. Relative progenitor cell levels and cardiovascular outcomes. A) Progenitor cell levels 
(mean ± standard error) in patients divided into those who developed or not developed an event (all 
events, 3-point MACE, 4-point MACE) at follow-up. B) Annual incidence of all events, 3-point 
MACE, and 4-point MACE in patients divided according to high or low stem/progenitor cell levels 
based on the median value. *p<0.05; **significant after BH correction.  
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Figure 6. Absolute progenitor cell levels and cardiovascular outcomes. A) Progenitor cell levels 
(mean ± standard error) in patients divided into those who developed or not developed an event (all 
events, 3-point MACE, 4-point MACE) at follow-up. B) Annual incidence of all events, 3-point 
MACE, and 4-point MACE in patients divided according to high or low stem/progenitor cell levels 
based on the median value. *p<0.05; **significant after BH correction. 
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Figure 7. Kaplan-Meier curves. The panels show fully adjusted event-free survival curves for the 
primary outcome (all events) from Cox proportional hazard regression analyses in patients with low 
versus high levels of CD34+ cells (left) or CD34+CD133+ cells (right). 
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Figure 8. Meta-analysis flow-chart.  
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Figure 9. Quality of studies included in the meta-analysis. The percentage of studies satisfying 
each of the 16 items modified from the REMARK guidelines is reported. Studies excluded from 
meta-analysis (n=7) are not shown. 
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Figure 10. Forest plot of the risk for future cardiovascular events associated with a low versus 
a high CPC / EPC count. Separated results are shown for each different phenotype of progenitor 
cells. Therefore, studies reporting risk estimates associated with the levels of different phenotypes 
are reported more than once. The group called “Overall” reports subtotal risk estimates for each 
phenotype and a pooled risk ratio. Weights of each study, and individual risk ratios with 95% C.I. 
are shown, along with tests for heterogeneity and overall effect. CFU, colony forming cells. 
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Figure 11. Sub-analyses. For cardiovascular events (a), all-cause mortality (b), restenosis (c), and 
revascularization (d), up to 5 subanalyses are reported. Subanalysis 1 was performed excluding 
studies conducted only in patients with acute CVD. Subanalysis 2 was performed excluding studies 
for which the risk estimate had to be calculated. Subanalysis 3 was performed only including 
studies conducted only in patients with acute CVD. Subanalysis 4 was performed only with higher 
quality studies (>10 REMARK items). Subanalysis 5 was performed only with studies having a 
homogeneous definition of the composite cardiovascular endpoint (>50% hard events). 
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Figure 12. Forest plot of cardiovascular (a) and all-cause (b) mortality risk associated with a 
low versus a high CPC / EPC count. Separated results are shown for each different phenotype of 
progenitor cells. Weights of each study, and individual risk ratios with 95% C.I. are shown, along 
with tests for heterogeneity and overall effect. 
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Figure 13. Forest plot of the risk of restenosis (a) and revascularization (b) associated with a 
low versus a high CPC / EPC count. Separated results are shown for each different phenotype of 
progenitor cells. Weights of each study, and individual risk ratios with 95% C.I. are shown, along 
with tests for heterogeneity and overall effect. CFU, colony forming cells. 
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Figure 14. Meta-regression analysis. The natural log of the risk ratio for cardiovascular events is 
plotted against various characteristics of each study. Size of the bubbles is proportional to the 
weight of each study according to the random effect model. The regression lines and p-values are 
shown. 
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Figure 15. Funnel plots. Funnel plots have been constructed for all phenotypes versus 
cardiovascular events and all-cause mortality. 
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TABLES 
Table 1. Baseline clinical characteristics of study patients. *p<0.05 in patients with progression versus non-progression of microvascular disease. 
** p<0.05 in patients with versus without cardiovascular events. 
 
Variable All UAER 
development / 
progression 
Retinopathy  
development / 
progression 
Neuropathy  
development / 
progression 
Cardiovascular events 
No Yes No Yes No Yes No Yes 
Number 187 166 21 159 28 169 18 139 48 
Age, years 63.7±0.7 63.8±0.7 63.1±2.5 63.4±0.8 65.5±1.2 64.0±0.7 60.9±1.4 63.3±0.7 65.1±1.5 
Sex male, % 67 67 67 67 71 67 72 65 75 
BMI, kg/m2 29.5±0.4 29.5±0.4 29.0±1.0 29.4±0.4 30.0±1.1 29.3±0.4 31.6±1.3 29.1±0.4 30.7±0.9 
HbA1c, % 7.9±0.1 7.9±0.1 7.7±0.3 7.8±0.1 8.4±0.3* 7.9±0.1 8.2±0.4 7.8±0.1 
(62±1) 
8.3±0.3 
(67±2) 
Duration, years 10.4±0.6 10.5±0.7 9.6±2.2 10.2±0.7 11.7±1.7 10.5±0.7 9.5±1.3 10.4±0.8 10.3±1.1 
Hypertension, % 84 85 81 83 93 83 94 80 98** 
Dyslipidemia, % 81 83 71 82 75 81 83 82 79 
Smoke, % 13 11 29* 14 7 12 22 13 15 
Microangiopathy          
ACR, mg/g 76.3±16.3 79.4±18.2 47.9±16.1 66.8±16.1 127.6±58.0 55.9±10.8 263.0±129.7* 51.4±14.9 148.0±45.5** 
eGFR, ml/min 81.7±1.6 82.2±1.7 77.8±4.5 81.5±1.7 83.2±4.8 81.7±1.7 82.1±4.5 83.9±1.8 75.6±3.4** 
Retinopathy, % 22 22 24 21 26 22 22 20 28 
Neuropathy, % 13 13 14 12 22 14 11 13 15 
Macroangiopathy        53 75** 
CAD, % 15 14 19 14 18 15 11 10 29 
PAD, % 17 17 14 16 21 15 28 12 31 
Subclinical 
atherosclerosis, % 
48 47 57 47 57 48 50 45 58 
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Variable All UAER 
development / 
progression 
Retinopathy  
development / 
progression 
Neuropathy  
development / 
progression 
Cardiovascular events 
No Yes No Yes No Yes No Yes 
Diabetes therapy          
Insulin, % 47 46 48 44 61 46 56 42 58 
Secretagogues, % 42 44 24* 38 61* 41 44 40 48 
Metformin, % 72 73 62 72 71 73 56 76 60 
TZD, % 5 5 5 5 7 5 11 6 2 
Incretins, % 9 8 10 10 0* 9 0* 10 4 
Other medications          
Anti-platelet, % 49 49 48 47 64 49 50 45 63 
Statins, % 72 72 67 72 71 73 56 71 75 
ACE-inhibitors, % 54 54 52 55 50 54 50 53 58 
ARBs, % 24 25 19 23 32 24 28 21 33 
Beta-blockers, % 25 26 14 26 14 27 6* 20 38** 
Calcium-antagonists, 
% 
27 27 33 25 43 27 33 20 48** 
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Table 2. Baseline clinical characteristics of study patients divided according to the median value of 
each CPC (a) and EPC (b) level. *p<0.05 in paired comparisons 
 
 
Table 2a 
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Table 2b 
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Table 3. Logistic multiple regression analysis describing the association between CPC/EPC 
phenotypes and microvascular outcomes. All models are adjusted for age, sex, BMI, HbA1c, 
diabetes duration, hypertension, dyslipidemia, smoking, macroangiopathy, and duration of follow-
up. *not significant after FDR control with the BH procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 CD34+  
(for 1 SD decrease) 
CD133+KDR+ 
(for 1 SD decrease) 
CD34+CD133+KDR+ 
(for 1 SD decrease) 
OR  
(95% C.I.) 
p OR  
(95% C.I.) 
p OR  
(95% C.I.) 
p 
UAER 2.34 
(1.36-3.32) 
0.008 2.56 
(1.36-3.72) 
0.011 3.79 
(1.75-5.58) 
0.009 
CKD 1.56 
(0.84-2.28) 
0.124 0.94 
(0.30-1.57) 
0.859 1.39 
(0.33-2.38) 
0.466 
Retinopathy 1.89 
(1.14-2.64) 
0.020 1.28 
(0.62-1.93) 
0.402 1.22 
(0.44-1.96) 
0.571 
Neuropathy 1.97 
(1.03-2.90) 
0.042* 2.55 
(1.27-3.78) 
0.018 2.28 
(0.79-3.65) 
0.091 
Microangiopathy 2.54 
(1.88-3.19) 
<0.001 1.53 
(1.04-2.01) 
0.034* 1.90 
(1.21-2.56) 
0.011 
59 
 
Table 4. Hazard ratios (95% C.I.) for cardiovascular events in patients with low versus high relative 
or absolute levels of the 6 stem/progenitor cell phenotypes. All analyses of time to event were 
adjusted for BMI, HbA1c, hypertension, albumin/creatinine ratio, eGFR, macroangiopathy, therapy 
(insulin, metformin, incretins, anti-platelet agents, angiotensin receptor blockers, beta-blockers, 
calcium-antagonists). The analyses of time to death were adjusted for age, dyslipidemia, 
neuropathy, peripheral arterial disease and therapy (secretagogues, beta-blockers, calcium 
antagonists). *significant after BH correction. 
Cell type  
(low versus high level) 
All events 3-point MACE 4-point MACE Death 
Relative CD34+ 2.21 (1.14-4.29) 
p=0.018 
2.70 (0.75-9.67) 
p=0.127 
1.78 (0.88-3.56) 
p=0.108 
1.41 (0.48-4.09) 
p=0.532 
Absolute CD34+ 1.89 (1.00-3.55) 
p=0.049 
2.14 (0.65-7.05) 
p=0.210 
1.65 (0.84-3.24) 
p=0.148 
1.53 (0.49-4.75) 
p=0.466 
Relative CD133+ 1.74 (0.90-3.36) 
p=0.100 
1.88 (0.60-5.89) 
p=0.277 
1.07 (0.99-1.15) 
p=0.113 
1.83 (0.61-5.51) 
p=0.283 
Absolute CD133+ 1.97 (0.99-3.93) 
p=0.054 
1.27 (0.44-3.65) 
p=0.660 
1.64 (0.79-3.39) 
p=0.186 
0.65 (0.22-1.92) 
p=0.435 
Relative CD34+CD133+ 2.98 (1.46-6.08) 
p=0.003* 
2.35 (0.76-7.32) 
p=0.140 
2.37 (1.13-4.98) 
p=0.023 
3.44 (0.96-12.38) 
p=0.058 
Absolute CD34+CD133+ 1.99 (1.01-3.93) 
p=0.048 
1.21 (0.42-3.53) 
p=0.722 
1.58 (0.78-3.20) 
p=0.209 
0.79 (0.25-2.55) 
p=0.696 
Relative CD34+KDR+ 1.06 (0.56-2.00) 
p=0.855 
1.31 (0.45-3.79) 
p=0.620 
0.78 (0.40-1.55) 
p=0.479 
1.12 (0.40-3.12) 
p=0.829 
Absolute CD34+KDR+ 1.03 (0.53-2.00) 
p=0.924 
0.73 (0.24-2.23) 
p=0.582 
0.73 (0.36-1.50) 
p=0.388 
0.93 (0.33-2.60) 
p=0.882 
Relative CD133+KDR+ 0.82 (0.40-1.65) 
p=0.570 
2.54 (0.70-9.18) 
p=0.155 
0.70 (0.33-1.48) 
p=0.356 
1.53 (0.47-5.18) 
p=0.474 
Absolute CD133+KDR+ 0.50 (0.25-1.03) 
p=0.059 
0.62 (0.18-2.10) 
p=0.442 
0.34 (0.16-0.73) 
p=0.009 
1.80 (0.59-5.49) 
p=0.300 
Relative 
CD34+CD133+KDR+ 
0.62 (0.31-1.23) 
p=0.172 
0.99 (0.31-3.15) 
p=0.985 
0.44 (0.21-0.93) 
p=0.031 
0.53 (0.17-1.67) 
p=0.281 
Absolute 
CD34+CD133+KDR+ 
0.56 (0.28-1.13) 
p=0.105 
0.60 (0.18-1.99) 
p=0.401 
0.33 (0.15-0.72) 
p=0.008 
0.33 (0.10-1.07) 
p=0.065 
 
60 
 
Table 5. Summary of the characteristics studies included in the meta-analysis. *studies  with acute CV events (excluded in subgroup analysis 1 and 
included in subgroup analysis 3). †studies where standardized HR was not directly provided (excluded in subgroup analysis 2, see Table S2 for 
statistical details). ‡studies with high risk of bias (excluded in subgroup analysis 4). §studies with high heterogeneity in CVE composite outcome 
(excluded in subgroup analysis 5). AMI: Acute myocardial infarction; ACS: Acute Coronary Syndrome; ESRD: End Stage Renal Disease; HD: 
Hemodialysis; HF: Heart Failure; MS: Metabolic Syndrome; PTCA: Percutaneous transluminal coronary angioplasty; REV: Revascularization; 
RES: Restenosis; CVE: Cardiovascular Events; RESHPF: High Power Field. 
 
 Q % 
(1/16) 
Country Follow-
up 
(months) 
Sample 
size 
Age (years) 
(MeanSD) 
Male 
(%) 
Smoke 
(%) 
CVD   
(%) 
Dyslipidemia 
(%) 
Diabetes 
(%) 
Hypertension 
(%) 
CKD 
(%) 
Statins 
(%) 
Ace-
i/ARB 
(%) 
Population Phenotype Outcomes 
(event rate/yr) 
Chiang et al. 2014 † 93.3 Taiwan 48 77 68.514.5 81.8 48 89.6 59.7 54.5 76.6 59.7 48.5 36.3 Elective PTCA CD34+KDR+ CVE (8.7%) 
Pelliccia et al. 2013 † 68.7 Italy 60 155 61.110 59.3 26.4 21.9 45.1 14.1 47 n.a. 93.5 41.2 Elective PTCA 
CD34+KDR+ 
CD133+KDR+ 
CVE (8.4%) 
All death 
(2.1%) 
REV (5.2%) 
Briguori et al. 2010 † 81.2 Italy 24 136 63.513.9 74.2 30.8 36 54.4 42.6 81.6 39.7 88.2 n.a. Elective PTCA CFU 
RES (18.1%) 
CVE (21.6%) 
Bonello et al. 2012 † 68.7 France 6 156 64.711.4 75.6 29.5 n.a. 58.3 21.8 57.1 n.a. 69.9 81.4 Elective PTCA CD34+KDR+ REV (34.6%) 
Schober et al. 2005 ‡ 50 Germany 8 17 668 n.a. 47 47 82.3 29.4 76.4 n.a. 82.3 64.7 Elective PTCA CD34+ RES (61.7%) 
Wu et al. 2014  62.5 Taiwan 12 130 6613 36 11 20 18 37 58 100 16 20 PTCA of HD access 
CD34+KDR+ 
CD34+CD133+KDR+ 
RES (28%) 
Haine et al. 2014† 62.5 Belgium 6 124 613.5 77 26 11.2 82 n.a. 54 n.a. n.a. n.a. Elective Stenting CD34+KDR+ RES (n.a.) 
Patel et al. 2015  68.7 UK 22.4 905 62.612.4 63.4 79 26.2 75 31.8 80.6 
 
72.7 n.a. 
Elective coronary 
angiography 
CD34+ 
CD34+CD133+ 
CD34+KDR+ 
CVE (5.4%) 
CV death 
(4.4%) 
All death 
(4.2%) 
Lee et al. 2015  81.2 Korea 20 70 58.112.9 59 n.a. 27 31 41 87 100 29 n.a. ESRD on HD CD34+KDR+ CVE (16.2%) 
Maruyama et al. 2008  75 Japan 23 216 6511 56.4 29.6 n.a. n.a. 48.6 72.7 100 12.5 40.3 ESRD on HD CD34+ 
CVE (10.3%) 
All death 
(3.1%) 
Lorenzen et al. 2010 † 75 Germany 36 265 6615 55.4 9.8 84.5 n.a. 34.3 81.8 100 56.6 29 ESRD on HD CFU CVE (13.7%) 
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 Q % 
(1/16) 
Country Follow-
up 
(months) 
Sample 
size 
Age (years) 
(MeanSD) 
Male 
(%) 
Smoke 
(%) 
CVD   
(%) 
Dyslipidemia 
(%) 
Diabetes 
(%) 
Hypertension 
(%) 
CKD 
(%) 
Statins 
(%) 
Ace-
i/ARB 
(%) 
Population Phenotype Outcomes 
(event rate/yr) 
Lu et al. 2016 75 Taiwan 50 154 6915.3 46.7 16.2 n.a n.a. 55.8 68.8 100 n.a. n.a. ESRD on HD CD34+CD133+KDR+ 
CV death 
(6,3%) 
All death 
(12.2%) 
Werner et al. 2005  75 Germany 12 507 66.610.8 67.1 22.9 39 79.3 29 85.2 17.9 55.2 55.4 
Elective coronary 
angiography 
CD34+KDR+ 
CVE (42.2%) 
CV death 
(4.5%) 
All death 
(8.4%) 
REV (32.1%) 
Alba et al. 2013 † 62.5 Canada 7 156 5511 77 n.a. 7 59 24 42 100 54 92 Chronic HF CD34+KDR+ 
CVE (70.3%) 
All death 
(13.1%) 
Fadini et al. 2009 68.7 Italy 34 214 56.313 55.1 21 34.5 44.3 36.9 52.3 9.8 n.a. n.a. MS+Healthy 
CD34+ 
CD133+ 
CD34+CD133+ 
CD34+KDR+ 
CD133+KDR+ 
CD34+CD133+KDR+ 
CVE (6.1%) 
All death 
(3.4%) 
Schmidt-Lucke et al. 
2005 ‡§ 
50 Germany 10 120 57.212.6 81.6 34.1 64.1 n.a. 14 50.8 n.a. 20 54.1 CHD+Healthy+ACS CD34+KDR+ CVE (11%) 
Shimoni et al. 2016 75 Israel 20 241 7710 39.4 14.1 43.9 73.4 34.8 80.5 n.a. 70.1 51 Aortic Stenosis CD34+KDR+ 
CV Death 
(9.9%) 
Cuadrado et al. 2015 * 62.5 Spain 6 150 57,39.8 84,6 68 4 27 16 40.6 n.a. 0 n.a. AMI+Acute Stroke CD34+CD133+KDR+ CVE (25.3%) 
Yu et al. 2013 *†‡§ 43.7 Korea 48 40 596.8 50 55 n.a. 45 30 45 n.a. 100 n.a. AMI 
CD34+ 
CD133+ 
CVE (7.5%) 
Padfield et al. 2013 * 62.5 UK 36 201 6111 84 66 31.8 75 15 52 n.a. n.a n.a. PTCA for ACS CD34+ REV (11.6%) 
Martì-Fabrega et al. 
2014 * 68.7 
Spain 29 
121 
70.112.6 65.3 22.2 19.8 35.5 28.1 76 n.a. 30.6 n.a. 
Acute Stroke CD34+CD133+KDR+ CVE (6.1%) 
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Table 6. Summary of characteristics of all the patients (n=4,155) included in the meta-analysis. 
 
 
 
 
 
  
  
 
 
 
  
 
 
Follow-up months 
(weight meanSD) 
22.49.7 
Age, years  
(weight meanSD) 
63.811.6 
Male sex (%) 63.7 
Smoke (%) 39.9 
Previous CVD (%) 34.5 
Dyslipidemia (%) 62.8 
Diabetes (%) 31.5 
Hypertension (%) 69.7 
Statins (%) 58.4 
Ace-i/ARB (%) 50.5 
